专利检索 ap:("Merck Sharp & Dohme LLC" OR "Pfizer Inc.") AND inv:"Samuel S. Engel" 第 1 页

1.

发明授权
Methods of treating or reducing the risk of cardiovascular events and related diseases using SGLT-2 inhibitors 有权

公开(公告)号：US12036203B2

公开(公告)日：2024-07-16

申请号：US16597894

申请日：2019-10-10

申请人： Merck Sharp & Dohme LLC , Pfizer Inc.

发明人： Brett Lauring , Samuel S. Engel , Steven G. Terra , James M. Rusnak

IPC分类号： A61K31/357 , A61K31/155 , A61K31/4985 , A61K31/7048 , A61P9/04 , A61P9/10

CPC分类号： A61K31/357 , A61K31/155 , A61K31/4985 , A61K31/7048 , A61P9/04 , A61P9/10 , A61K31/4985 , A61K2300/00 , A61K31/7048 , A61K2300/00 , A61K31/155 , A61K2300/00

摘要： The present invention relates to the use of certain SGLT-2 inhibitors, such as ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof, for treating, reducing the risk of and/or preventing heart failure, myocardial infarction, cardiovascular disease or cardiovascular death in animals without type 2 or type 1 diabetes mellitus, or in animals with pre-diabetes, or in animals with type 2 or type 1 diabetes mellitus or pre-diabetes.

2.

发明申请
METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR EVENTS AND RELTED DISEASES USING SGLT-2 INHIBITORS 审中-公开

公开(公告)号：US20200038368A1

公开(公告)日：2020-02-06

申请号：US16597894

申请日：2019-10-10

申请人： Merck Sharp & Dohme Corp. , Pfizer Inc.

发明人： Brett Lauring , Samuel S. Engel , Steven G. Terra , James M. Rusnak

IPC分类号： A61K31/357 , A61K31/155 , A61K31/7048 , A61K31/4985 , A61P9/10 , A61P9/04

摘要： The present invention relates to the use of certain SGLT-2 inhibitors, such as ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof, for treating, reducing the risk of and/or preventing heart failure, myocardial infarction, cardiovascular disease or cardiovascular death in animals without type 2 or type 1 diabetes mellitus, or in animals with pre-diabetes, or in animals with type 2 or type 1 diabetes mellitus or pre-diabetes.